Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2A6 | P11509 | 13/20 | 0.48 |
| ▸ | CYP2B6 | P20813 | 12/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 12/20 | 0.48 |
| ▸ | CYP2E1 | P05181 | 12/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 11/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 10/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 10/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 9/20 | 0.48 |
| ▸ | CYP2C8 | P10632 | 7/20 | 0.48 |
| ▸ | MAP3K5 | Q99683 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.39 |
| ▸ | LTA4H | P09960 | 1/20 | 0.38 |
| ▸ | AKT1 | P31749 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4376704 | 0.81 | MAP3K5 (0.59) | CYP2A6CYP2B6CYP2C19CYP2E1CYP3A4 | |
| SCHEMBL3349917 | 0.74 | AKT1 (0.44) | MAP3K5MAPK1AKT1 | |
| SCHEMBL3347541 | 0.72 | CLK1 (0.42) | CYP2A6CYP2B6CYP2C19CYP2E1CYP3A4 | |
| SCHEMBL3353473 | 0.71 | SGK1 (0.44) | CYP2A6CYP2B6CYP2C19CYP2E1CYP3A4 | |
| SCHEMBL29574366 | 0.68 | LTA4H (0.68) | CYP2A6CYP2B6CYP2C19CYP2E1CYP3A4 | |
| SCHEMBL6698000 | 0.66 | CYP2A6 (0.56) | CYP2A6CYP2B6CYP2C19CYP2E1CYP3A4 | |
| SCHEMBL23781572 | 0.66 | CYP2A6 (0.97) | CYP2A6CYP2B6CYP2C19CYP2E1CYP3A4 | |
| SCHEMBL23789558 | 0.66 | CYP2A6 (0.66) | CYP2A6CYP2B6CYP2C19CYP2E1CYP3A4 | |
| Iodide SCHEMBL29574376 | 0.66 | LTA4H (0.65) | CYP2A6CYP2B6CYP2C19CYP2E1CYP3A4 | |
| SCHEMBL30208793 | 0.65 | MAPK1 (0.51) | MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180370966-A1 | METHODS OF TREATMENT USING PYRIDINONYL PDK1 INHIBITORS | SUNESIS PHARMACEUTICALS, INC. | 2018-12-27 | — | — | US | disclosed |
| US-9873693-B2 | Methods of treatment using pyridinonyl PDK1 inhibitors | SUNESIS PHARMACEUTICALS, INC. (US) | 2018-01-23 | — | — | US | disclosed |
| US-8778977-B2 | Pyridinonyl PDK1 inhibitors | SUNESIS PHARMACEUTICALS, INC. (US) | 2014-07-15 | — | — | US | disclosed |
| EP-2038272-B1 | PYRIDINONYL PDK1 INHIBITORS | SUNESIS PHARMACEUTICALS INC (US) | 2013-09-04 | — | — | EP | disclosed |
| US-20100144730-A1 | PYRIDINONYL PDK1 INHIBITORS | SUNESIS PHAMACEUTICALS (US) | 2010-06-10 | — | — | US | disclosed |
| EP-2038272-A2 | PYRIDINONYL PDK1 INHIBITORS | Sunesis Pharmaceuticals, Inc. (US) | 2009-03-25 | — | — | EP | disclosed |
| WO-2008005457-A2 | PYRIDINONYL PDK1 INHIBITORS | SUNESIS PHARMACEUTICALS (US) | 2008-01-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180370966-A1 | METHODS OF TREATMENT USING PYRIDINONYL PDK1 INHIBITORS | PDK1, PDK2, PDK3 | CYP2A6 4663/4885CYP2B6 4702/4885CYP2C19 4374/4885 |
| US-20100144730-A1 | PYRIDINONYL PDK1 INHIBITORS | PDK1, PDK2, PDK3 | CYP2A6 4576/4885CYP2B6 4593/4885CYP2C19 3922/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.